8-K: Ensysce Biosciences Amends Series C Preferred Stock Terms

Ensysce Biosciences, Inc. filed an amendment to its Series C Preferred Stock Certificate of Designation, removing a specific redemption clause.

Summary

• Ensysce Biosciences, Inc. filed an amendment to its Certificate of Designation for Series C Non-Voting Convertible Preferred Stock.
• The amendment, effective September 25, 2026, removes Section 6.5.3 and related references from the Series C Certificate of Designation.
• Section 6.5.3 previously allowed Series C Preferred Stock holders to redeem their shares for cash under specific conditions related to failure to deliver common stock.
• The conditions for redemption included a failure to deliver common stock in accordance with the terms of the Series C Preferred Stock, with redemption at fair value.
• The company also filed a Certificate of Correction for the Series C Certificate of Designation on August 6, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative development due to the removal of a redemption clause, which could impact preferred shareholder rights.

Positives

• Clarification of Series C Preferred Stock terms, potentially simplifying future transactions.
• Removal of a redemption clause that could have led to cash outflows under specific circumstances.

Negatives

• Removal of a redemption right for Series C Preferred Stock holders, potentially reducing their protections.
• The amendment removes a mechanism for preferred shareholders to exit their investment for cash if common stock delivery fails.

Risks

• Potential for shareholder dissatisfaction among Series C Preferred Stock holders due to the removal of redemption rights.
• Uncertainty regarding the impact of this amendment on the future conversion of Series C Preferred Stock into common stock.
• The original Section 6.5.3 was a safeguard against potential failures in common stock delivery, and its removal might increase risk for preferred holders in such scenarios.

Future Outlook

The filing does not contain specific forward-looking statements or guidance. The amendment primarily addresses existing terms of preferred stock.

Management Comments

• The amendment was effective upon filing on September 25, 2026.

Industry Context

StockSavvy.ai notes that amendments to preferred stock terms are common as companies navigate financing and operational milestones. The removal of a redemption clause can be a strategic move to preserve cash or simplify capital structure, but it may also alter the risk-reward profile for preferred shareholders.

Corporate Governance

Stakeholder Impact

• Shareholders: Series C Preferred Stock holders may experience a reduced level of protection due to the removal of a cash redemption option. Common Stock holders may see a simplified capital structure.
• Creditors: No direct impact mentioned.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.

Next Steps

• The company will operate under the amended Series C Certificate of Designation.
• Future actions will depend on the company's strategy regarding its Series C Preferred Stock and common stock conversion.

Key Dates

Keywords

Series C Preferred Stock, Certificate of Designation, Amendment, Redemption Clause, Convertible Preferred Stock, Shareholder Approval, Common Stock, Delaware Corporation